April 19th 2024
Following an investigation that began in November 2023, the FDA now requires boxed warnings regarding T-cell malignancies on all BCMA- and CD19-directed T-cell products.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
T-Cell Redirection Therapy Shows Promise As Salvage Therapy in R/R Multiple Myeloma
September 15th 2022In a retrospective analysis of 115 patients with relapsed/refractory multiple myeloma who progressed after therapy on a bispecific antibody, researchers found that the myeloma patients can be salvaged with sequential T-cell redirection therapy.
Read More
CLDN6 CAR T-Cell Therapy Elicits Clinical Activity in Relapsed/Refractory Advanced Solid Tumors
September 9th 2022The investigational carcinoembryonic antigen claudin 6–directed CAR T-cell therapy BNT211-01 displayed clinical activity in combination with a CLDN6-encoding mRNA vaccine in patients with CLDN6-positive relapsed/refractory advanced solid tumors.
Read More
Unmet Needs for Managing CRS and ICANS Due to CAR T-Cell Therapy
September 1st 2022Nicolas Gazeau, MS, discusses next steps and unmet needs following a positive retrospective study of anakinra for the management of neurotoxicity and cytokine release syndrome in patients who received chimeric antigen receptor T-cell therapy.
Watch
During a Targeted Oncology case-based roundtable event, Pallawi Torka, MD, discussed with participants when to consider a patient for chimeric antigen receptor T-cell therapy and what alternative treatments to use for a patient with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Dosing of Novel Autologous CAR T Cells and Nivolumab Begins in cHL Study
August 19th 2022Treatment with CD30 chimeric antigen receptor T-cell therapy combined with a monoclonal antibody has begun in the phase 1b ACTION study of patients with relapsed or refractory classical Hodgkin lymphoma.
Read More
CAR T-Cell Treatment at Higher Doses Reveal Beneficial Survival Data Without Worry of Added Toxicity
August 12th 2022Tisagenlecleucel boosted survival rates in children with B-cell lymphoblastic leukemia. Further research will be planned to examine the data and analyze additional clinical variables.
Read More
Second-Line Lisocabtagene Maraleucel Provides Benefit in Large B-Cell Lymphoma
August 10th 2022Findings from the phase 2 PILOT study reveal lisocabtagene maraleucel to provide benefit as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation.
Read More
Behind the FDA Approval: Liso-Cel for R/R Large B-Cell Lymphoma
June 30th 2022In an interview with Targeted Oncology, Manali Kamdar, discussed the recent FDA approval of lisocabtagene maraleucel for the treatment of patients with relapsed or refractory large B-cell lymphoma, and how community oncologists should approach patient referrals and post-treatment care.
Read More
Investigation of Novel CAR T Product, MB-106, in Various R/R B-Cell Malignancies
June 16th 2022In an interview with Targeted Oncology, Mazyar Shadman, MD, MPH, discussed his research of MB-106 as treatment for patients with relapsed or refractory B-non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Read More
Understanding CAR T-Cell Therapy Utilization Patterns in the Community Oncology Setting
June 8th 2022In an interview with Targeted Oncology™, Bruce Feinberg, DO, discussed the use of CAR T-cell therapy in the community oncology setting, the challenges oncologist face, and the next wave of innovation to improve CAR T-cell administration for patients.
Read More
Durable Response Elicited With CLDN18.2-Directed CAR T-cell Therapy in Gastrointestinal Cancers
June 5th 2022Treatment with a Claudin18.2–specific chimeric antigen receptor T-cell therapy has demonstrated either a response or stable disease in patients with heavily pretreated advanced gastric and pancreatic adenocarcinoma.
Read More
Community Providers Face Hurdles With CAR T-Cell Therapy Referrals and In-Office Infusion
June 3rd 2022Few community practices are performing in-office infusions on CAR T-cell therapy, but due to interest from 20% of them, experts recommend stakeholder alignment to address the concerns of the oncology population.
Read More
Blocking TIGIT May Help With Dipping Remission Rates in NHL After CAR T-Cell Therapy
May 19th 2022In preclinical study, researchers have identifies anti-TIGIT therapy as a potentially effective strategy for improving remission rates in patients with non-Hodgkin lymphoma after chimeric antigen receptor T-cell therapy.
Read More
High-Dose Anakinra Shows Promise in Treating CRS/ICANS Post CAR T-Cell Therapy
May 18th 2022In an interview with Targeted Oncology, Nicolas Gazeau, further discusses his analysis of anakinra when administered at 2 different dose regimens for patients with refractory CRS/ICANS after CAR T-cell therapy.
Read More
CAR T Cells Shown Effective Without Increased Risk of CRS or ICANS in CNS-Involved LBCL
April 25th 2022Looking at 4 CAR T-cell agents for the treatment of large B-cell lymphoma, a systematic review and analysis showed that these therapies do not appear to increase the risk of cytokine release syndrome or immune effector cell–associated neurotoxicity syndrome.
Read More